Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On March 3, 2025, we reported on a study presented at the 2025 American Academy of Allergy, Asthma, & Immunology Annual Meeting that was designed to compare anaphylaxis symptoms following neffy (epinephrine nasal spray; ARS Pharmaceuticals, Inc.) compared with other treatment.

The study

The phase 3 study, conducted in Japan (jRCT2031230143), included 15 patients aged 6 to 17 years who experienced at least grade 2 anaphylaxis symptoms during an oral food challenge. A matched control group of 15 patients, aged 6 to 20 years, was prospectively selected based on clinical and laboratory data. Researchers analyzed symptom progression using a mixed-effects model for repeated measures.

The findings

Compared with the control group, the neffy group had significantly fewer skin symptoms at 15, 20, and 30 minutes posttreatment (P <.01). Respiratory symptoms improved more rapidly in the neffy group at 5, 10, and 15 minutes (P <.01), while gastrointestinal symptoms were lower at 5 and 10 minutes (P <.05) and 15 minutes (P <.01). Total symptom scores were also lower in the neffy group at 10 and 15 minutes (P <.05, P <.01, respectively).

Authors' comments

"Relative to a matched control group, patients receiving neffy as an initial treatment had lower symptom scores within 10 minutes. These data suggest that neffy is a viable needle-free option for management of anaphylaxis."

Click here for more details.